What is Aciphex used for?

Aciphex

The active ingredient in ACIPHEX Delayed-Release Pills is rabeprazole sodium, a substituted benzimidazole that prevents gastric acid secretion.

Healing of Erosive or Ulcerative GERD

Rabeprazole (aciphex generic name) is suggested for short term ( 4 to 8 weeks ) therapy in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux illness ( GERD ) . For the people who may have not healed after eight weeks of therapy, an extra 8-week course of ACIPHEX might be considered.

Maintaining of Treatment of Erosive or Ulcerative GERD

ACIPHEX is indicated for sustaining healing and decrease in relapse rates of symptoms of heartburn in patients with erosive or ulcerative gastroesophageal reflux illness (GERD Maintaining). Managed tests will not extend beyond 1 year.

Treatment of Symptomatic GERD

ACIPHEX is suggested for the therapy of day time and bed time heartburn along with other symptoms related to GERD in older people and adolescents twelve years of age and above.

Treatment of Duodenal Ulcers

ACIPHEX is suggested for short term (up to 4 weeks) therapy in the healing and symptomatic relief of duodenal ulcers. Most people heal within 4 weeks.

Helicobacter pylori Eradication to Decrease the Risk of Duodenal Ulcer Recurrence
ACIPHEX along with amoxicillin and clarithromycin as a 3 drug routine is suggested for the treating patients with H. Pylori disease and duodenal ulcer illness (active or history within the past five years) to eliminate H. pylori. Eradication of H. Pylori continues to be shown to decrease the risk of duodenal ulcer recurrence. Therapy of Pathological Hypersecretory Problems, Such as Zollinger-Ellison Syndrome.

ACIPHEX is suggested for the long term therapy of pathological hypersecretory problems, such as Zollinger-Ellison syndrome.

Generic Aciphex – Rabeprazole Sodium – Aciphex Side Effects and Adverse Reactions
Worldwide, over 2900 patients happen to be treated with rabeprazole in Phase II-III medical trials including different dosages and cycles of treatment.
Mainly because medical trials are carried out under different conditions, adverse reaction rates observed in the medical trials of a medicine cannot be instantly as compared to rates in the medical trials of another medicine and might not reflect the rates noticed in practice.

Medical Tests Experience

The information described below reveal exposure to ACIPHEX in 1064 patients exposed for about eight weeks. The researches were primarily placebo- and active-controlled tests in patients with Erosive or Ulcerative Gastroesophageal Reflux Illness (GERD), Duodenal Ulcers and Gastric Ulcers. The populace had a indicate age of 53 years (range 18-89 years) and had a ratio of around 60% male/ 40% female. The racial distribution was 86% Caucasian, 8% African American, 2% Asian and 5% other. The majority of patients received either 10 mg, 20 mg or 40 mg/day of ACIPHEX.

An examination of adverse reactions appearing in ? 2% of ACIPHEX patients ( n=1064 ) and with an even greater frequency compared to placebo ( n=89 ) in controlled North American and European serious treatment tests , exposed the following adverse reactions : pain ( 3% vs. . 1% ) , pharyngitis ( 3% vs. . 2%) , flatulence ( 3% vs. . 1% ) , disease ( 2% vs. . 1% ) , and constipation ( 2% vs. . 1% ) .

The three long term maintaining research consisted of a total of 740 patients ; a minimum of 54% of patients were exposed to rabeprazole for six months while a minimum of 33% were exposed for 1 year . Of the 740 patients , 247 ( 33% ) and 241 ( 33% ) patients received 10 mg and 20 mg of ACIPHEX , respectively , while 169 ( 23% ) patients received placebo and 83 ( 11% ) received omeprazole .

The basic safety profile of rabeprazole in the maintaining studies was consistent with that which was observed in the serious studies.
Aciphex (Rabeprazole Sodium) – symptoms and Aciphex Dosage

Symptoms And Usage

Treatment of Erosive or Ulcerative GERD
ACIPHEX is suggested for short term (4 to 8 weeks) therapy in the curing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For all those patients who may have not cured after eight weeks of treatment, an extra 8-week period of ACIPHEX might be considered.

Maintaining of Treatment of Erosive or Ulcerative GERD
ACIPHEX is suggested for maintaining treatment and decrease in relapse rates of symptoms of heartburn in patients with erosive or ulcerative gastroesophageal reflux illness (GERD Maintenance). Managed tests will not extend beyond 1 year.
Treatment of Symptomatic GERD

ACIPHEX is suggested for the treating daytime and bed time heartburn along with other symptoms related to GERD in older people and adolescents 12 years of age and above.

 

Related Articles:

 

Leave a Reply

Your email address will not be published. Required fields are marked *

*